The cannabinoid CB 1 receptor and the endocannabinoid anandamide: possible antidepressant targets
Expert Opinion on Therapeutic Targets October 14, 2008 Francis Rodriguez Bambico, Gabriella Gobbi 80 citations
Major depression is the most common mental disorder, but current antidepressants have limited effectiveness. Recent research suggests that drugs activating cannabinoid CB(1) receptors or enhancing endocannabinoid levels have antidepressant-like effects, while the CB(1) antagonist rimonabant increases depression and suicide risk. CB(1) agonists and fatty acid amide hydrolase (FAAH) inhibitors work similarly to existing antidepressants by boosting serotonin and norepinephrine transmission and promoting new neuron growth in the hippocampus. FAAH inhibitors cause fewer adverse cannabinoid effects and have a wider therapeutic window than direct CB(1) agonists. However, because the endocannabinoid system also affects peripheral body functions, side effects require attention.